Treatment could spur production of insulin in Type 1 diabetes

June 18, 2014 by Morgan Sherburne
Credit: Darren Lewis/public domain

Combining two different medications could help patients with Type 1 diabetes at least partially regain the ability to produce their own insulin, a University of Florida study has shown.

Dr. Michael Haller, a pediatric endocrinologist, likens his approach to treating Type 1 diabetes to a game of cops and robbers. First, he ferrets out problematic cells of the immune system that could be behind a patient's inability to produce insulin and wipes them out with a medication called Thymoglobulin, a drug initially developed for use in organ transplantation. Then he uses a medication called Neulasta, a drug designed to improve the lives of people with certain forms of cancer, to stimulate the production of new and potentially beneficial immune cells. Haller presented the results of the study on Sunday at the annual meeting of the American Diabetes Association in San Francisco.

"The treatment is almost like trying to hit the reset button on the immune system," Haller said. "We're trying to wipe out the bad cells and stimulate the good cells at the same time."

Haller treated 17 adult Type 1 for two weeks with the cocktail therapy and then followed them for a year. Another eight patients were given a placebo. By the end of the year, the patients treated with the cocktail had increased their ability to produce insulin. This indicates that the Thymoglobulin was successful in killing the bad cells, and the Neulasta was successful in stimulating new, healthy immune cells. The researchers also say the patients' ability to produce insulin indicates they had an increase in beta cells, the cells responsible for producing insulin in the pancreas.

According to conventional diabetes wisdom, within just a few months of the onset of Type 1 diabetes, there are very few of the insulin-producing beta cells left in the pancreas, said Mark Atkinson, a co-investigator in this study and member of the department of pathology, immunology and laboratory medicine. That the treatment seemed to stimulate insulin production in people with established Type 1 diabetes made the researchers "cautiously optimistic," Atkinson said.

"The results that Dr. Haller saw in his first study are profound," Atkinson said.

The study was also novel in that it worked with patients who had been long diagnosed with the disease. Typically, studies examine patients who are newly diagnosed and still have a reasonable number of beta cells producing insulin. The patients in Haller's study had been living with Type 1 diabetes between four months and two years.

"The model has mostly been to test therapies aimed at beta cell preservation in people who have just been diagnosed," Haller said. "But obviously, the majority of patients living with the disease have been living with the disease for a long time, so people become disenfranchised from the research process. We're interested in making life better for these patients."

Atkinson began considering Thymoglobulin as a treatment for diabetes nearly a decade ago. He and fellow co-investigator Dr. Desmond Schatz, associate chairman of the department of pediatrics, authored a paper advocating a combination approach to treating Type 1 diabetes. Based on Schatz's belief in so-called combination therapies, the group began shepherding a cocktail of Thymoglobulin and Neulasta through early studies done with mouse models.

"Despite tremendous strides in our understanding of the natural history of Type 1 diabetes, we are as yet unable to cure and prevent the disease," Schatz said. "This study is a step in that direction, toward a biological cure."

The patients in Haller's study will be followed for three to five years to see if their bodies will preserve the insulin-producing . The researchers' next step will be to recruit patients who have been newly diagnosed with the disease to conduct a larger trial.

Haller says he hopes the approach will help patients manage their disease more easily.

"If we can confirm the results in a larger effort, the study could potentially be paradigm-shifting for our field in that it documents we should really be looking at combination therapies in treating Type 1 diabetes," Haller said. "Our ultimate goal is to prevent and cure this disease, but we have to crawl before we walk, and walk before we run. This study is an important step forward in our efforts to make life easier for with Type 1 ."

Explore further: Reversal of type 1 diabetes in mice may eventually help humans

Related Stories

Reversal of type 1 diabetes in mice may eventually help humans

June 15, 2014
Investigators at the University of Cincinnati (UC) have found a therapy that reverses new onset Type 1 diabetes in mouse models and may advance efforts in combating the disease among humans.

Antibody affinity is decisive in Type 1 diabetes in adults

March 11, 2014
Patients with LADA – a form of autoimmune type 1 diabetes in adulthood – can be distinguished from patients with non-autoimmune type 2 diabetes by means of the antibody reaction affinity to the enzyme glutamic acid decarboxylase ...

Novel drug target linked to insulin secretion and type 2 diabetes treatment

May 26, 2014
A signal that promotes insulin secretion and reduces hyperglycemia in a type 2 diabetes animal model is enhanced by the inhibition of a novel enzyme discovered by CHUM Research Centre (CRCHUM) and University of Montreal researchers. ...

Drug preserves beta cells in new cases of type 1 diabetes

August 6, 2013
(Medical Xpress)—A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes. Results of the phase 2 trials are published ...

Insulin 'still produced' in most people with type 1 diabetes

October 9, 2013
New technology has enabled scientists to prove that most people with type 1 diabetes have active beta cells, the specialised insulin-making cells found in the pancreas. Type 1 diabetes occurs when the body's immune system ...

T-cell targeted therapy tested in type 1 diabetes study

August 27, 2013
Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network (ITN), ...

Recommended for you

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

Immune system killer cells increase risk of diabetes

July 6, 2017
More than half of the German population is obese. One effect of obesity is to chronically activate the immune system, placing it under continuous stress. Researchers in Jens Brüning's team at the Max-Planck-Institute for ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.